Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.48 |
| ▸ | CCR5 | P51681 | 3/20 | 0.48 |
| ▸ | CCR8 | P51685 | 3/20 | 0.48 |
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550924 | 1.00 | KDM4E (0.50) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL3423163 | 0.86 | KDM4E (0.50) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL16806017 | 0.85 | KDM4E (0.50) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL17427076 | 0.84 | KDM4E (0.57) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL9225738 | 0.83 | CCR1 (0.49) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL5330963 | 0.83 | NPC1 (0.49) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL30776779 | 0.82 | KDM4E (0.55) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL13581443 | 0.82 | KDM4E (0.55) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL1129367 | 0.81 | KDM4E (0.47) | KDM4ENPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL17306381 | 0.81 | KDM4E (0.47) | KDM4ENPC1RAB9ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| CN-117285572-A | Cyclometalated platinum complex, and preparation method and application thereof | 昆明理工大学 | 2023-12-26 | — | — | CN | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | KDM4E 769/4885NPC1 763/4885RAB9A 2648/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | KDM4E 769/4885NPC1 763/4885RAB9A 2648/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | KDM4E 769/4885NPC1 763/4885RAB9A 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.